Comparison of Aromatase Inhibitors Expands Treatment Options for Women Requiring Hormonal Therapy for Early Stage Breast Cancer

(April 19, 2018)

CancerConnect News: According to an Italian research team the three aromatase inhibitors approved for the treatment of postmenopausal hormone receptor–positive early stage breast cancer have no significant differences in effectiveness or safety, For... Continue Reading


First Interim Analysis in SEQUOIA Phase 3 Pancreatic Cancer Study

(April 18, 2018)

CancerConnect News: The first interim analysis of the SEQUOIA clinical study evaluating the novel immunotherapy drug pegilodecakin in patients with pancreatic cancer will continue to enroll patients based on The Data Monitoring Committee first interim... Continue Reading


Overall Health, Not Just Age, is an Important Factor in Treatment of Non-Small Cell Lung Cancer

(April 11, 2018)

Younger patients with non-small cell lung cancer (NSCLC) are more likely to receive treatment than older patients, regardless of overall health and prognosis, according to the results of a study published in the Journal of Clinical Oncology. Lung cancer... Continue Reading


Managing Side Effects From EGFR Inhibitors

(April 10, 2018)

CancerConnect News: Epidermal Growth Factor Receptor (EGFR) inhibitor drugs are a type of precision cancer medicine commonly used to treat lung, colon, head and neck and other cancers that over express the EGFR.  There are several EGFR inhibitor drugs... Continue Reading


Rubraca® Approved as Maintenance Treatment of Recurrent Ovarian Cancer

(April 9, 2018)

CancerConnect News: Rubraca® (rucaparib) has been approved for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.... Continue Reading


Tafinlar® + Mekinist® Demonstrates Long Term Survival Benefit for BRAF Mutation-Positive Metastatic Melanoma

(April 5, 2018)

CancerConnect News: Metastatic melanoma patients with the BRAF V600 mutation treated with the combination of Tafinlar® (dabrafenib) + Mekinist® (trametinib) can experience long term cancer free survival according to results presented at the 53rdAnnual... Continue Reading


Precision Cancer Treatment with Afinitor Encouraging in Uterine Cancer

(April 4, 2018)

CancerConnect News: Combination therapy with Afinitor (everolimus) and Femara (letrozole) demonstrated encouraging activity in the treatment of advanced endometrial cancer, according to a report from the Society of Gynecologic Oncologists meeting this... Continue Reading


Spring into Action For Oral, Head, and Neck Cancer Awareness Week!

(April 3, 2018)

CancerConnect News: As the month of April brings head and neck cancer into focus, it’s time to increase public understanding of the disease, including its prevalence, approaches to screening and prevention, treatment options, and resources that offer... Continue Reading


Breakthrough Therapy Designation Awarded for Enfortumab Vedotin in Locally Advanced or Metastatic Bladder Cancer

(April 3, 2018)

CancerConnect News: The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to enfortumab vedotin for patients with locally advanced or metastatic urothelial (bladder) cancer who were previously treated with checkpoint... Continue Reading


Nexavar Improves Survival for Patients with Rare Sarcomas

(March 28, 2018)

Interim results from a randomized clinical trial for patients with desmoid tumors or aggressive fibromatosis (DT/DF) show that the drug Nexavar (sorafenib tosylate) extended progression-free survival compared with a placebo. Progression-free survival... Continue Reading


AbbVie and the International Myeloma Foundation Partner to Study Role of a Genetic Mutation in Multiple Myeloma

(March 28, 2018)

AbbVie a research and development-based global biopharmaceutical company, and the International Myeloma Foundation (IMF) today announced they have entered into a collaboration to conduct a landmark retrospective chart review study to better understand... Continue Reading


FDA Approves Perjecta for Adjuvant Treatment of HER2-positive Breast Cancer

(March 26, 2018)

CancerConnect News: On December 20, 2017, the Food and Drug Administration granted regular approval to Perjeta (pertuzumab) for use in combination with Herceptin (trastuzumab) and chemotherapy as adjuvant treatment of patients with HER2-positive early... Continue Reading


Next Page »